Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer.
Dorssers
Lambert C J
LC
Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam, The Netherlands.
Grebenchtchikov
Nicolai
N
Brinkman
Arend
A
Look
Maxime P
MP
Klijn
Jan G M
JG
Geurts-Moespot
Anneke
A
Span
Paul N
PN
Foekens
John A
JA
Sweep
C G J Fred
CG
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology; D050719:Crk-Associated Substrate Protein; D004797:Enzyme-Linked Immunosorbent Assay; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D011506:Proteins / Q000032:analysis*; D050717:Retinoblastoma-Like Protein p130; D013629:Tamoxifen / Q000627:therapeutic use*
C493841:BCAR1 protein, human; D014408:Biomarkers, Tumor; D050719:Crk-Associated Substrate Protein; D004965:Estrogen Antagonists; D011506:Proteins; D050717:Retinoblastoma-Like Protein p130; D013629:Tamoxifen